Today we can influence overweight and obesity – and thus prevent their consequences, as is the development of diabetes or cardiovascular disease

Czech version

Published in: Diab Obez 2021; 21(41): 56-58
Category: News

Sources

WHO Global Health Observatory Data Repository (online database). World Health Organization: Geneva 2013. Dostupné z WWW: <http://apps.who.int/gho/data/view.main>.
Marketing of foods high in fat, salt and sugar to children: update 2012–2013. WHO Regional Office for Europe: Copenhagen 2013. ISBN 978 92 890 009 3. Dostupné z WWW: <https://www.euro.who.int/__data/assets/pdf_file/0019/191125/e96859.pdf>.
Národný Program Prevencie Obezity (National Obesity Prevention Program). Ministry of Health: Bratislava 2008.
Jensen MD, Ryan DH, Apovian CM et al. [American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Obesity Society]. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines and the Obesity Society. Circulation 2014; 129(25 Suppl 2): S102-S138. Dostupné z DOI: <http://dx.doi.org/10.1161/01.cir.0000437739.71477.ee>.
Heymsfield SB, van Mierlo CA, van der Knaap HC et al. Weight management using a meal replacement strategy: meta- and pooling-analyssi from six studies. Int J Obes Relat Metab Disord 2003; 27(5): 537–549. Dostupné z DOI: <http://dx.doi.org/10.1038/sj.ijo.0802258>.
Wadden TA, Walsh OA, Berkowitz RI et al. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. Obesity (Silver Spring) 2019; 27(1): 75–86. Dostupné z DOI: <http://dx.doi.org/10.1002/oby.22359>.
Wadden TA, Tronieri JS. Sugimoto D et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE INT randomized controlled trial. Obesity (Silver Spring) 2020; 28: 529–536. Dostupné z DOI: <http://dx.doi.org/10.1002/oby.22726>.
Food and Drug Administration. Ozempic (semaglutide) injection, for subcutaneous use (prescribing information). Informace dostupné z WWW: <http://www.fda.gov>.
Ahrén B, Masmiquel L, Kumar H et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidine-diones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol 2017; 5(5): 341–354. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(17)30092-X>.
Ahmann AJ, Capehorn M, Charpentier G et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care 2018; 41(2): 258–266. Dostupné z DOI: <http://dx.doi.org/10.2337/dc17–0417>.
O’Neil PM, Birkenfeld AL, McGowan B et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018; 392(10148): 637–649. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)31773–2>.
Kushner RF, Calanna S, Davies M et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring) 2020; 28: 1050–1061. Dostupné z DOI: <http://dx.doi.org/10.1002/oby.22794>.
Webb VL, Wadden TA. Intensive lifestyle intervention for obesity: principles, practices, and results. Gastroenterology 2017; 152(7): 1751–1764. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2017.01.045>.
Gabery S, Salinas CG, Paulsen SJ et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 2020; 5(6): e133429. Dostupné z DOI: <http://dx.doi.org/10.1172/jci.insight.133429>.
Friedrichsen M, Breitschaft A, Tadayon S et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021;23(3): 754–262. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14280>.
Wing RR, Lang W, Wadden TA et al. Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34(7): 1481–1486. Dostupné z DOI: <http://dx.doi.org/10.2337/dc10–2415>.
Ryan DH, Yockey SR. Weight loss and improvements in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep 2017; 6(2): 187–194. Dostupné z DOI: <http://dx.doi.org/10.1007/s13679–017–0262-y>.
Gregg EW, Chen H, Wagenknecht LE et al. [Look AHEAD Research Group]. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012; 308(23): 2489–2496. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2012.67929>.
Kuna ST, Reboussin DM, Strotmeyer ES et al. Sleep AHEAD Research Subgroup of the Look AHEAD Research Group. Effects of weight loss on obstructive sleep apnea severity: ten-year results of the Sleep AHEAD study. Am J Respir Crit Care Med 2021; 203(2): 221–229. Dostupné z DOI: <http://dx.doi.org/10.1164/rccm.201912–2511OC>.
Bettge K, Kahle M, Abd El Aziz MJ et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017; 19(3): 336–347. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12824>.